Reversing cardiac remodelling and improving outcomes in heart failure: what are our first-choice treatments
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Reversing cardiac remodelling and improving outcomes in heart failure: what are our first-choice treatments?

Industry Discoveries organised by Novartis

Novartis
Title
Speaker
Slides
Video
Q&A
  • Title: Introduction
    Speaker: CS Lam (Singapore,SG), P Seferovic (Belgrade,RS)

    NA

    Video:

    Q&A:
     
  • Title: Cardiac remodelling in heart failure – the implications for patients.
    Speaker: W Mullens (Genk,BE)

    NA

    Video:

    Q&A:
     
  • Title: Cardiac remodelling in patients treated with sacubitril/valsartan – what have studies shown?
    Speaker: M Guazzi (San Donato Milanese,IT)

    NA

    Video:

    Q&A:
     
  • Title: Based on what we know today, what should be the foundational therapy for heart failure patients? Summary and Conclusion.
    Speaker: CS Lam (Singapore,SG)

    NA

    Video:

    Q&A:
     
  • Title: Reversing cardiac remodelling and improving outcomes in heart failure: what are our first-choice treatments?
    Speaker: CS Lam (Singapore,SG), P Seferovic (Belgrade,RS), W Mullens (Genk,BE), M Guazzi (San Donato Milanese,IT)

    NA

    Video:

    Q&A:
     

The content of these presentations reflects the personal opinion of the author/s and is not necessarily the official position of the European Society of Cardiology.

 

  Back to the Industry Discoveries

About the ESC
Press and Media
Information
Follow us

         

 Need help?

 Help centre
 Contact us

© 2025 European Society of Cardiology. All rights reserved.